Business
Inside information: Bioretec adjusts and restates previously reported net sales FOR H1/2025 and does not expect accelerated sales in 2025
On 22 November 2024, Bioretec Ltd ("Bioretec" or the "Company"), announced through a press release a new sales and distribution agreement with Tri-State Biologics ("TSB"), enabling the sale and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area (the "TSB Distribution Agreement"). The TSB Distribution Agreement was, upon its signing, based on a stocking distribution model, whereby TSB first purchase
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Inside information 27 October 2025 at 9.14 p.m. EEST","length":75,"tagName":"p"},{"type":"text","content":"TAMPERE, Finland, Oct. 27, 2025 /PRNewswire/ -- On 22 November 2024, Bioretec Ltd ("Bioretec" or the "Company"), announced through a press release a new sales and distribution agreement with Tri-State Biologics ("TSB"), enabling the sale and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut, and Massachusetts area (the "TSB Distribution Agreement"). The TSB Distribution Agreement was, upon its signing, based on a stocking distribution model, whereby TSB first purchases products from Bioretec for further sale and distribution by TSB to hospitals in the target geography.","length":696,"tagName":"p"},{"type":"text","content":"Following the signing of the TSB Distribution Agreement, it became evident that the sales of Bioretec's products in 2025 were not progressing in line with expectations of the TSB Distribution Agreement, and a product repurchase addendum was added on 5 May 2025 to the TSB Distribution Agreement, whereby Bioretec would repurchase from TSB such unpaid products for which TSB was unable to procure purchasers within the payment terms ("Repurchase Addendum"). Following such repurchase under the Repurchase Addendum, Bioretec could then distribute such unpaid products directly to end-users itself, similarly to direct distribution models to which Bioretec is aiming to shift towards in an effort to move away from stocking distribution models.","length":755,"tagName":"p"},{"type":"text","content":"In its unaudited half-year report covering the financial period from 1 January 2025 to 30 June 2025 published on 14 August 2025 (the "H1 Report"), Bioretec reported net sales of approximately EUR 2.06 million. The net sales in the H1 Report included the sales proceeds of the full stock of products initially sold by Bioretec to TSB in the amount of approximately EUR 0.52 million. The net sales in the H1 Report, however, did not take into account the addition of the Repurchase Addendum under the TSB Distribution Agreement and the resulting potential for Bioretec to repurchase products from TSB. As a result, the net sales reported by Bioretec in the H1 Report we...